Endothelin receptor antagonism in patients with chronic heart failure

Cardiovascular Research

Volumn 47, Issue 1, 2000, Pages 166-172

  Love, Michael P ^a   Ferro, Charles J ^b   Haynes, William G ^b   Plumpton, Christopher ^c   Davenport, Anthony P ^c   Webb, David J ^b   McMurray, John J V ^d  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d W Infirm Glasgow Dumbarton R ^*  (United Kingdom)

Author keywords

Endothelins; Heart failure; Receptors; Vasoconstriction dilation

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NORLEUCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART FAILURE; HUMAN; PRIORITY JOURNAL; VASODILATATION;

CASE-CONTROL STUDIES; FOREARM; HEART FAILURE, CONGESTIVE; HUMANS; MALE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; PLETHYSMOGRAPHY; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; VASODILATOR AGENTS; VASOMOTOR SYSTEM;

EID: 0034123658     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00081-X     Document Type: Article

References (35)

1. Love M.P., McMurray J.J.V. Endothelin in chronic heart failure; current position and future prospects. Cardiovasc Res. 31:1996;665-674.
2. Sakai S., Miyauchi T., Sakurai T., et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Circulation. 93:1996;1214-1222.
3. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long term survival in heart failure. Nature. 384:1996;353-355.
4. Mulder P., Richard V., Derumeaux G., et al. Role of endogenous endothelin in chronic heart failure. Circulation. 96:1997;1976-1982.
5. Love M.P., Haynes W.G., Gray G.A., Webb D.J., McMurray J.J.V. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 94:1996;2131-2137.
6. Kiowski W., Sütsch G., Hunziker P., et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
7. Sütsch W., Bertel O., Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther. 10:1996;717-725.
8. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-732.
9. Sakurai T., Yanagisawa M., Takuwa Y., et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature. 348:1990;732-735.
10. Seo B., Oemar B.S., Siebenmann R., von Segesser L., Lüscher T.F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 89:1994;1203-1208.
11. Haynes W.G., Strachan F.E., Webb D.J. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 92:1995;357-363.
12. de Nucci G., Thomas R., D'Orléans-Juste P., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA. 85:1988;9797-9800.
13. Love M.P., Haynes W.G., Webb D.J., McMurray J.J.V. Venous endothelin receptor function in patients with chronic heart failure. Clin Sci. 98:2000;65-70.
14. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 344:1994;852-854.
15. Verhaar M.C., Strachan F.E., Newby D.E., et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and endothelin-B receptor blockade. Circulation. 97:1998;752-756.
16. Cannan C.R., Burnett J.C. Jr., Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation. 93:1996;646-651.
17. Wada A., Tsutamoto T., Fukai D., et al. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol. 30:1997;1385-1392.
18. Ihara M., Noguchi K., Saeki T., et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 50:1992;247-255.
19. Ishikawa K., Ihara M., Noguchi K., et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA. 91:1994;4892-4896.
20. Wei C.-M., Lerman A., Rodeheffer R.J., et al. Endothelin in human congestive heart failure. Circulation. 89:1994;1580-1586.
21. Pacher R., Stanek B., Hülsmann M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 27:1996;633-641.
22. Xu D., Emoto N., Giaid A., et al. ECE-1: a membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:1994;473-485.
23. Strachan FE, Gray GA, Webb DJ. Antagonism of ETB mediated venoconstriction by BQ-788 in human veins in vivo [abstract]. Br J Clin Pharmacol 2000 (in press).
24. Benjamin N., Calver A., Collier J., Robinson B., Vallance P., Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 25:1995;918-923.
25. Plumpton C., Haynes W.G., Webb D.J., Davenport A.P. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol. 116:1995;1821-1828.
26. Plumpton C., Haynes W.G., Webb D.J., Davenport A.P. Measurement of C-terminal fragment of big endothelin-1: a novel method for assessing the generation of endothelin-1 in humans. J Cardiovasc Pharmacol. 26:(suppl 3):1995;34-36.
27. B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 33:1999;932-938.
28. Strachan F.E., Spratt J.C., Wilkinson I.B., Johnston N.R., Gray G.A., Webb D.J. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension. 33:1999;581-585.
29. Collier J.G., Lorge R.E., Robinson B.F. Comparison of effects of tolmesoxide (RX71107), diazoxide, hydralazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 5:1978;35-44.
30. Berrazeuta J.R., Bhagat K., Vallance P., MacAllister R.J. Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol. 44:1997;569-571.
31. Hemsén A., Ahlborg G., Ottosson-Seeberger A., Lundberg J.M. Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept. 55:1995;287-297.
32. Frelin C., Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res. 28:1994;1613-1622.
33. Zolk O., Quattek J., Sitzler G., et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 99:1999;2118-2123.
34. Maguire J.J., Davenport A.P. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for upregulation of endothelin-converting enzyme activity in disease. Br J Pharmacol. 125:1998;238-240.
35. Galatius-Jensen S., Wroblewski H., Emmeluth C., Bie P., Haunso S., Kastrup J. Plasma endothelin in congestive heart failure: effect of the ACE inhibtor fosinopril. Cardiovasc Res. 32:1996;1148-1154.